Edgewood Oncology anounced first patients dosed in phase 2a study of BTX-A51 in genetically-defined breast cancer. Chemenu supplies novel building blocks chemenu.com/col/BTX-A51.ht… #BTX-A51 #CDK7 #CDK9 #ER+ #HER2- #MetastaticBreastCancer #GATA3 #Chemenu #buildingblocks

New📰| Selective #CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive #BreastCancer | Full text in Clinical Cancer Research. Cristina Guarducci Rinath Jeselsohn Geoffrey Shapiro MD PhD Albert Grinshpun ➡️pubmed.ncbi.nlm.nih.gov/38381406/

New study now out in Clinical Cancer Research: Selective #CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor positive #BreastCancer. Cristina Guarducci Rinath Jeselsohn Geoffrey Shapiro MD PhD pubmed.ncbi.nlm.nih.gov/38381406/

Rinath Jeselsohn, MD (Rinath Jeselsohn) presented a talk on #CDK7 inhibition in ER+ #BreastCancer: Mechanisms of action and reversal of CDK4/6 inhibitor resistance in today's DF/HCC Breast Cancer Program Research Retreat.

#SHR5428 is a Selective and #Orally Active #CDK7 Inhibitor for Breast #Cancer Research #SHR5428 shows high selectivity over #CDK1, #CDK2, #CDK4, #CDK6, #CDK9, #CDK12 in CDK family. For more detailed information: medchemexpress.com/shr5428.html cancer-research-network.com/2023/10/09/shr…

Mechanism for Synergistic Effect of #TOPO1 and #CDK7 Inhibitors in Small Cell Lung Cancer (#SCLC): ➡️DNA Damage and Repair: A Topo1 inhibitor triggers DNA breaks and forms DNA-protein crosslink (DNA-DPC) complexes, leading to cell damage. Such damage impedes transcription and

Delighted to see our latest paper on #CDK7 and chromosome instability in #breastcancer in press Journal of Biological Chemistry! Congrats to Katrina Piemonte, PhD and Bryan Webb! MSTP at Case Western Reserve University Cleveland Clinic Lerner Research Institute Case Comp Cancer Ctr #bcsm jbc.org/cms/attachment…

2/ Of course, since it takes a considerable amount of time for new biologics pipelines to enter clinical trials, produce meaningful data, and enter the market, they only partially let go of their specialty until then. ➡️Next-Cabozantinib: #zanzalintinib ➡️XL102: #CDK7 inhibitor

👉Paper Recommendation: Identification of #CDK7 Inhibitors from Natural Sources Using Pharmacoinformatics and Molecular Dynamics Simulations mdpi.com/2227-9059/9/9/… via Biomedicines MDPI Topic: #Pharmacoinformatics

Christiane Kuempers et al 📄 CDK7 is a prognostic biomarker for non-small cell lung cancer Available here #CDK7 #LungCancer #LCsm #ThoracicOncology #OpenAccess fro.ntiers.in/K8ot

📄 CDK7 is a prognostic biomarker for non-small cell lung cancer 👨‍⚕️👩‍⚕️ Christiane Kuempers et al Available here #OpenAccess 👉 fro.ntiers.in/K8ot #CDK7 #LungCancer #LCsm #ThoracicOncology

"#CDK7 Inhibition Is Effective in all the #Subtypes of #Breast #Cancer: Determinants of Response and Synergy with #EGFR Inhibition" from McDermott et al. #cellsmdpi #cellbiology #CDK7 #breastcancer Full text: mdpi.com/2073-4409/9/3/…

Can I get a #CDK7 👀

Grinding #CDK7

Still live on bo2 twitch.tv/Imcdkog #CDK7

"Study of #Samuraciclib a first-in-class, oral, selective inhibitor of #CDK7, in combination with fulvestrant in patients with advanced hormone receptor-positive, HER2-negative Breast Cancer" interesante revisión de la Dra. Denisse Lee #SABCS FUCAM Cáncer de Mama OncoAlert BreastCancerTrials.org

General session 3 at #SABCS21: interesting preliminary data with #samuraciclib an oral selective #CDK7 inhibitor combined with #fulvestrant in #HR+/#HER2- advanced #BreastCancer patients progressing on CDK4/6 inhibitor-based first-line therapy OncoAlert #bcsm SABCS